Sagimet Biosciences Presents Preclinical Results Supporting Therapeutic Potential Of Its FASN Inhibitor In Combination With Semaglutide And A Comprehensive Lipidomic Analysis Of Interim Fascinate-2 Data At AASLD
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences has presented preclinical results that show the therapeutic potential of its FASN inhibitor in combination with semaglutide. The combination treatment improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver fibrosis. The FASCINATE-2 Phase 2b clinical trial of denifanstat in F2-F3 NASH patients is fully enrolled and is on track to report week 52 topline results in the first quarter of 2024.
November 10, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sagimet Biosciences' preclinical results show potential for its FASN inhibitor in combination with semaglutide. The FASCINATE-2 Phase 2b clinical trial is fully enrolled and results are expected in Q1 2024.
The positive preclinical results for Sagimet Biosciences' FASN inhibitor, combined with the fact that the FASCINATE-2 Phase 2b clinical trial is fully enrolled and on track, could potentially have a positive impact on the company's stock in the short term. The results of the trial, expected in Q1 2024, could further influence the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100